Meta-analysis shows low risk of muscle pain from statins

In over 90% of cases, statin therapy is not related to muscle pain, researchers from a large new study reported on August 29, 2022 in The Lancet. “The idea that statins may cause frequent muscle pain has been a persistent belief among some patients and clinicians, however our study confirms that the statin is rarely the cause of muscle pain […]

Could time limits on opioid prescriptions reduce misuse?

Most people who get a prescription for opioid painkillers to ease the pain of an operation or dental procedure fill it right away. But a new study shows that some fill these prescriptions more than a month later – long after the acute pain from their care should have subsided. In 2019, 1% of opioid prescriptions from dentists and surgeons […]

Very high doses of CBD, a cannabis component, don’t affect driving

Millions of consumers and patients around the world will be heartened by the results of the latest study on cannabis and driving. The University of Sydney-led research finds that 1500mg, the highest daily medicinal dose of cannabidiol (CBD), has no impact on people’s driving or cognitive abilities. CBD is a cannabis component widely used for medical as well as ‘wellness’ […]

New health professional training blueprint to transform chronic pain care

Researchers have developed a new national blueprint to help health professionals support the one in five Australians living with chronic pain, costing the Australian economy $139 billion every year. Published in leading international interdisciplinary pain journal PAIN, the ‘Listen to me, learn from me’ framework was co-developed by a national team of Curtin University-led researchers and collaborators working in partnership with […]

FSA publishes list of permitted CBD products

The UK has become the first country in the world to regulate the market for safe, oral cannabidiol (CBD) products with the release on 31st March of the Food Standards Agency’s (FSA) public list of cannabinoid (CBD) products permitted for sale to consumers. Publication of the list represents a key step in the path to full authorisation, expected in 2023. […]